An experimental therapy for a rare blood cancer, Ebvallo, was unexpectedly rejected by the FDA despite internal recommendations for approval, indicating a potentially higher approval threshold for rare disease treatments. Direct-to-consumer websites like TrumpRx are struggling to lower drug prices for patients with commercial insurance due to drug discount laws aimed at low-income Americans, raising pressure on insurers to adapt policies. For content creators, these events highlight the importance of covering regulatory changes and their impacts on patient access and pricing in pharmaceutical news.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
Views63
Ali NematiBlogUI.author_articles
